Health & business, drug dealers cut. And do not ... - The Daily

classic scene of the girl in a miniskirt waiting in the waiting room now no longer valid. Ditto for the colleague who sits in front of the doctor requesting the conference in late May: Amalfi Coast or Cinque Terre, work program minimized to enjoy the boat trip or the fish in the dish. Nothing to do everything all over and very forbidden by the new regulation Farmindustria .

Via who no longer need

pharmaceutical today he dropped the category of ‘ informant doctor . This is confirmed by the investigation 23 top managers (by Pfizer AstraZeneca) under investigation by Milan prosecutors to have slipped into a bad company 1.200 sellers, people ended early due to road bankruptcy were no longer needed, were eliminated. “Now the business of health care is stuff for huge fish – says an informant – With the cuts in public funding and a hunger for more and more aggressive policy, the only convenience of the big houses do is lobby in the upper echelons, push products in the protocols of care, have the ok of control bodies for new patents. Wasting time with the door-to-door is no longer needed, and even then not serve us. “

Who is

s’adegua and does somersaults in order to bring home a paycheck. Yet the fund does not show the suffering series, given the context. “The pharmaceutical market will close 2013 with a positive trend (+2.4% on the cumulative January-September), driven by the performance of specialist and hospital sector, while the channel pharmacy is stable, “said Quotidianosanita.it Sergio Liberatore , general manager of IMS Health Italy , a company that organizes the pharmaceutical marketing. And in the short to medium term? “The pharmaceutical market will be hampered by the effects of the economic crisis and the resulting cost containment by public administrations. Is the impact of possible budget overruns shelves of for pharmaceutical expenditure required to business. “

pyramid

The translation is simple: the market, despite everything, hold up. And the goal remains the primary public health, 110 billion euro that will be used in 2014 to prop up the system, including doctors, medicines and hospitals. The problem is that the bottom never enough . The overruns for the various items of expenditure has been a constant in recent decades: waste management and majestic scams have stolen considerable forces, but also the defense policies of the pharmaceutical lobby has prevented lower costs.

upstream of total health budget set by the state is divided into a pyramid of progressively more detailed entries, from large basins national (medicines, hospitals, home care), through the regional powers to get to the shares of each of the individual products authorized to sell the house in Italy, at the agreed price. That is, for the pill X is established sale price and refund which will be borne by the national health service, but also the maximum number of pieces that each doctor may prescribe: X when the pill is sold over the set amount, the doctor is sanctioned and the manufacturer will be subject to payback , a kind of non-repayment .

The technique is used to hold the boost trade, and in 2012 he got a good result: how do you explain the ‘ AIFA (Italian Agency for the drug), the overall pharmaceutical – 25 billion and a half of euro – the roof for the medicines ordered study has substantially upright, while remaining important regional differences (the Sicilians have absorbed 1,110 daily doses per 1000 inhabitants in Bolzano 743 of 1000). Sforata brutally instead the hospital pharmaceutical expenditure (out of 101%) is worth 5 billion euro compared with 20 of the territory, but it bodes well for the future.

Target hospital

Explain the Director General of AIFA, Luca Pani : “So far the pharmaceutical expenditure has offset the increase in the hospital. But when it brings the roof of the territorial minimum limit sealing, we do not have more space to compensate for that hospital. Given that the latter salt, because the new drug fortune are coming on the market, but they cost so much and are administered in the hospital, this will presumably be modified expenditure ceilings . Just raise the roof dell’ospedaliera and the system will hold up very well. “

So, rather than the traditional recipe: the Italian market, which has always lived in harmony with the policy, it must find a new economic pact in the Parliament. Especially because from here to 2018 will expire dozens of patents fundamental to modern pharmacology, and the whole game of generics will be offset by new products. Who is going to produce? And who will sell in Italy, sixth world market for the drug?

U.S. superstar

idea comes from ranking of the top seller in our country. In the lead is the American Pfizer , the largest pharmaceutical company in the world that in Italy a turnover of over one billion Euros. The U.S. team (Pfizer and others) totals $ 5 billion in revenue, 13 thousand employees and expresses Federfarma president Massimo Scaccia, managing director of Janssen Cilag (Johnson & Johnson). A true battleship that defends the body of national production, 26 billion in revenue and 63 thousand employees, with the induced double-digit becoming the technology of the Italian flower, a gem quality export voted (67%) and the threat always in the barrel: if you are not as convenient to us, let’s hurry to leave. Ministers, councilors, health directors and medical complacent so far have little to argue whether a month ago has been arrested yet another regional advisor on charges of having favored a clan of the Camorra Procurement ASL Caserta, and if the owners of the most important Italian house, Menarini, were indicted last June for tax evasion, money laundering and corruption. A scam in the National Health Service.

from The Daily of December 27, 2013